Pacira BioSciences PCRX 深 沪
等待开盘 10-07 09:30:00 美东时间
24.76
-0.290
-1.16%
华盛通- 最 高26.91
- 今 开25.13
- 成交量 46.82万股
- 最 低 23.65
- 昨 收 25.05
- 总市值 112.50万
- 52周最高 27.66
- 市盈率 静 26.91
- 换手率 1030.43%
- 52周最低 18.80
- 委 比 -98.62%
- 总股本 4.54万
- 历史最高 121.95
- 量 比 0.95
- 振 幅 13.01%
- 历史最低 1.10
- 每 手 1
- 风险率 1.71%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pacira BioSciences Divests Iovera To Zimmer Biomet For Up To $140M
Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the divestiture of iovera ®° to Zimmer
06-30 19:36
Earnings Scheduled For April 30, 2026
Companies Reporting Before The Bell • Sonic Automotive (NYSE:SAH) is projected ...
04-30 19:11
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
2025-11-06 19:12
Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025
Pacira BioSciences released a film titled *The Next Frontier: Mark & Leah’s Story*, highlighting the journey of a couple who overcame opioid dependency through non-opioid pain management, emphasizing the importance of alternative treatments in transforming lives.
2025-06-18 12:00
Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee
Pacira BioSciences' PCRX-201, a novel gene therapy for knee osteoarthritis, demonstrated sustained improvements in pain, stiffness, and function for up to three years with a single injection, showing excellent safety and efficacy in Phase 1 trials.
2025-06-11 12:00
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences授予19名新员工激励奖，包括26,700股期权和41,600股限制性股票单位，归属期四至五年。
2025-06-05 12:00
Expert Ratings For Pacira BioSciences
In the latest quarter, 14 analysts provided ratings for Pacira BioSciences (NAS...
2024-09-25 00:00
Jefferies Maintains Buy on Pacira BioSciences, Raises Price Target to $18
Jefferies analyst Glen Santangelo maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and raises the price target from $15 to $18.
2024-09-24 23:43
